The FDA has approved the marketing of a 10 topical gel formulation of the muscarinic receptor antagonist oxybutynin chloride (Gelnique-Watson) for treatment of overactive bladder. Oxybutynin is also available for this indication as oral tablets, an oral syrup and a transdermal patch.1
展开▼
